Laekna (HKG:2105) completed the phase I single ascending dose study (SAD Study) of LAE102 for treating obesity, according to a Monday filing with the Hong Kong bourse.
Studies have been carried out in China and the US. LAE102 is a monoclonal antibody that specifically targets ActRIIA, a receptor involved in muscle regeneration and fat metabolism, the filing added.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。